Australia's most trusted
source of pharma news
Friday, 30 January 2026
Posted 29 January 2026 AM
AstraZeneca will petition the Federal Court next week for an interlocutory injunction to prevent Pharmacor listing on the PBS a generic version of its kidney disease drug Forxiga.
Last November Pharmacor registered two brands of Forxiga generics on the ARTG, Glixafor and Pharmacor dapagliflozin. They weren't the first generics - that win went to Cipla in 2022 - and they weren't the last, with Sandoz registering further brands a week afterwards.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.